Shant Manoushagian in New York, New York

Medical School: Sorry, his university is not listed
Graduation Year: 2012
The Primary Medical Specialty for Shant Manoushagian is listed as: Cardiovascular Disease (cardiology)
Approximate Years of Experience: 12
PAC (PECOS ID)#: 2365796752
NPI #: 1205191699
NPI Created On: 07/11/2012
NPI Last Updated Listed as: 02/23/2021
Primary Taxonomy Code: 207RC0000X
License Number:
MD457729
Listed Gender: Male

Services and Procedures include:

1. Nuclear medicine study of vessels of heart using drugs or exercise multiple studies
2. Nuclear medicine study of vessels of heart using drugs or exercise multiple studies
3. Routine ekg using at least 12 leads including interpretation and report
4. Routine electrocardiogram (ekg) using at least 12 leads with interpretation and report
5. Exercise or drug-induced heart and blood vessel stress test with ekg monitoring, physician supervision, interpretation, and report
6. Exercise or drug-induced heart and blood vessel stress test with ekg monitoring and physician supervision
7. Exercise or drug-induced heart and blood vessel stress test with ekg monitoring, physician interpretation and report
8. Ultrasound examination of heart including color-depicted blood flow rate, direction, and valve function
9. Ultrasound examination of heart including color-depicted blood flow rate, direction, and valve function
10. Follow-up or limited ultrasound examination of heart
11. Insertion of probe in esophagus for heart ultrasound examination including interpretation and report
12. Doppler ultrasound study of heart blood flow, valves, and chambers
13. Follow-up or limited heart doppler ultrasound study of heart blood flow, valves, and chambers
14. Doppler ultrasound study of color-directed heart blood flow, rate, and valve function
15. Established patient office or other outpatient, visit typically 25 minutes
16. Initial hospital inpatient care, typically 50 minutes per day
17. Subsequent hospital inpatient care, typically 35 minutes per day
18. Technetium tc-99m tetrofosmin, diagnostic, per study dose
19. Injection, perflutren lipid microspheres, per ml